

CLAIMS

We claim:

1. A targeting construct comprising:
 - (a) a first polynucleotide sequence homologous to a CX2 gene;
 - (b) a second polynucleotide sequence homologous to the CX2 gene; and
 - (c) a selectable marker.
2. The targeting construct of claim 1, wherein the targeting construct further comprises a screening marker.
3. A method of producing a targeting construct, the method comprising:
 - (a) providing a first polynucleotide sequence homologous to a CX2 gene;
 - (b) providing a second polynucleotide sequence homologous to the CX2;
 - (c) providing a selectable marker; and
 - (d) inserting the first sequence, second sequence, and selectable marker into a vector, to produce the targeting construct.
4. A method of producing a targeting construct, the method comprising:
 - (a) providing a polynucleotide comprising a first sequence homologous to a first region of a CX2 gene and a second sequence homologous to a second region of a CX2 gene;
 - (b) inserting a positive selection marker in between the first and second sequences to form the targeting construct.
5. A cell comprising a disruption in a CX2 gene.
6. The cell of claim 5, wherein the cell is a murine cell.
7. The cell of claim 6, wherein the murine cell is an embryonic stem cell.
8. A non-human transgenic animal comprising a disruption in a CX2 gene.
9. A cell derived from the non-human transgenic animal of claim 8.
10. A method of producing a transgenic mouse comprising a disruption in a CX2 gene, the method comprising:
 - (a) introducing the targeting construct of claim 1 into a cell;
 - (b) introducing the cell into a blastocyst;
 - (c) implanting the resulting blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and
 - (d) breeding the chimeric mouse to produce the transgenic mouse.
11. A method of identifying an agent that modulates the expression of a CX2, the method comprising:

- (a) providing a non-human transgenic animal comprising a disruption in a CX2 gene;
- (b) administering an agent to the non-human transgenic animal; and
- (c) determining whether the expression of CX2 in the non-human transgenic animal is modulated.

12. A method of identifying an agent that modulates the function of a CX2, the method comprising:

- (a) providing a non-human transgenic animal comprising a disruption in a CX2 gene;
- (b) administering an agent to the non-human transgenic animal; and
- (c) determining whether the function of the disrupted CX2 gene in the non-human transgenic animal is modulated.

13. A method of identifying an agent that modulates the expression of CX2, the method comprising:

- (a) providing a cell comprising a disruption in a CX2 gene;
- (b) contacting the cell with an agent; and
- (c) determining whether expression of the CX2 is modulated.

14. A method of identifying an agent that modulates the function of a CX2 gene, the method comprising:

- (a) providing a cell comprising a disruption in a CX2 gene;
- (b) contacting the cell with an agent; and
- (c) determining whether the function of the CX2 gene is modulated.

15. The method of claim 13 or claim 14, wherein the cell is derived from the non-human transgenic animal of claim 8.

16. An agent identified by the method of claim 11, claim 12, claim 13, or claim 14.

17. A transgenic mouse comprising a disruption in a CX2 gene, wherein the transgenic mouse exhibits at least one of the following phenotypes: increased body weight, increased body length, or increased body weight to body length ratio as compared to wild-type mice.

18. A transgenic mouse comprising a disruption in a CX2 gene, wherein the transgenic mouse exhibits at least one of the following phenotypes: increased tolerance to glucose or increased ability to metabolize glucose as compared to wild-type mice.

19. A transgenic mouse comprising a disruption in a CX2 gene, wherein the transgenic mouse exhibits a decrease in response threshold to metrazol.

20. A method of producing a transgenic mouse comprising a disruption in a CX2 gene, wherein the transgenic mouse exhibits at least one of the following phenotypes according to claim 17, claim 18, or claim 19, the method comprising:

- (a) introducing a CX2 gene targeting construct into a cell;
(b) introducing the cell into a blastocyst;
(c) implanting the resulting blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and
(d) breeding the chimeric mouse to produce the transgenic mouse comprising a disruption in a CX2 gene.

21
31.

A cell derived from the transgenic mouse of claim 17, claim 18, claim 19, or claim 20.

22
32.

A method of identifying an agent that ameliorates a phenotype associated with a disruption in a CX2 gene, the method comprising:

- (a) administering an agent to a transgenic mouse comprising a disruption in a CX2 gene; and
(b) determining whether the agent ameliorates at least one of the following phenotypes: : increased body weight, increased body length, or increased body weight to body length ratio as compared to wild-type mice.

23
33.

A method of identifying an agent which modulates CX2 expression, the method comprising:

- (a) administering an agent to the transgenic mouse comprising a disruption in a CX2 gene; and
(b) determining whether the agent modulates CX2 expression in the transgenic mouse, wherein the agent has an effect on at least one of the following: : increased body weight, increased body length, or increased body weight to body length ratio as compared to wild-type mice.

24
34.

A method of identifying an agent which modulates CX2 gene function, the method comprising:

- (a) providing a cell comprising a disruption in a CX2 gene;
(b) contacting the cell with an agent; and
(c) determining whether the agent modulates CX2 gene function, wherein the agent modulates a phenotype associated with a disruption in a CX2 gene.

25
35.

The method of claim 35, wherein the phenotype comprises at least one of the following: increased body weight, increased body length, or increased body weight to body length ratio as compared to wild-type mice.

26
36.

An agent identified by the method of claim 32, claim 33, claim 34, or claim 35.

27
37.

An agent that modulates the function, expression or activity of a CX2 gene.

SUB
A
CONT.

~~28~~
39. A method of ameliorating a condition associated with impaired glucose tolerance, the method comprising administering to a subject in need, a therapeutically effective amount of an agent that modulates CX2 function, expression or activity.

add B1

09900518-070604